CMG Pharmaceutical Co. Ltd (058820) — Cash Flow-to-Debt Ratio
CMG Pharmaceutical Co. Ltd (058820) has a Cash Flow-to-Debt Ratio of -0.04x as of December 2025, meaning its operating cash flow of ₩-4.08 Billion could theoretically repay 0% of its total liabilities (₩104.41 Billion) in one year. See 058820 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CMG Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for CMG Pharmaceutical Co. Ltd across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of CMG Pharmaceutical Co. Ltd.
Annual Cash Flow-to-Debt Ratio for CMG Pharmaceutical Co. Ltd (2014–2025)
Year-by-year debt coverage analysis for CMG Pharmaceutical Co. Ltd. Check 058820 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | ₩-11.02 Billion | ₩104.41 Billion | ▼ -4244.1% |
| 2024 | 0.00x | ₩290.09 Million | ₩113.89 Billion | ▼ -96.6% |
| 2023 | 0.08x | ₩3.91 Billion | ₩51.87 Billion | ▼ -56.8% |
| 2022 | 0.17x | ₩4.94 Billion | ₩28.31 Billion | ▼ -55.2% |
| 2021 | 0.39x | ₩5.63 Billion | ₩14.47 Billion | ▲ +87.9% |
| 2020 | 0.21x | ₩2.94 Billion | ₩14.22 Billion | ▼ -11.4% |
| 2019 | 0.23x | ₩2.82 Billion | ₩12.08 Billion | ▲ +173.9% |
| 2018 | 0.09x | ₩886.78 Million | ₩10.40 Billion | ▼ -49.1% |
| 2017 | 0.17x | ₩1.95 Billion | ₩11.62 Billion | ▼ -28.3% |
| 2016 | 0.23x | ₩2.31 Billion | ₩9.87 Billion | ▼ -5.7% |
| 2015 | 0.25x | ₩2.41 Billion | ₩9.73 Billion | ▲ +210.0% |
| 2014 | 0.08x | ₩724.89 Million | ₩9.07 Billion | — |